PriceTargets.com logo

LENZ Therapeutics - LENZ Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $44.00
  • Forecasted Upside: 345.80%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$9.87 As of 04/21/2026 05:00 PM ET
▼ -0.26 (-2.57%)

This chart shows the closing price for LENZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LENZ Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LENZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LENZ

Analyst Price Target is $44.00
▲ +345.80% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for LENZ Therapeutics in the last 3 months. The average price target is $44.00, with a high forecast of $67.00 and a low forecast of $26.00. The average price target represents a 345.80% upside from the last price of $9.87.

This chart shows the closing price for LENZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 contributing investment analysts is to moderate buy stock in LENZ Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/23/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/21/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/22/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/21/2026

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/21/2026HC WainwrightLower TargetBuy ➝ Buy$56.00 ➝ $48.00
3/26/2026CitigroupLower TargetBuy ➝ Buy$52.00 ➝ $26.00
3/25/2026Bank of AmericaLower TargetBuy ➝ Buy$35.00 ➝ $29.00
3/10/2026William BlairReiterated RatingOutperform ➝ Outperform
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025HC WainwrightReiterated RatingBuy ➝ Buy
11/20/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
10/27/2025HC WainwrightReiterated RatingBuy ➝ Buy$56.00
10/22/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
10/20/2025Raymond James FinancialReiterated RatingOutperform ➝ Outperform$40.00 ➝ $50.00
10/10/2025Piper SandlerBoost TargetOverweight ➝ Overweight$67.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/31/2025CitigroupReiterated RatingBuy ➝ Buy$45.00 ➝ $49.00
7/31/2025Raymond James FinancialBoost TargetOutperform ➝ Outperform$39.00 ➝ $40.00
7/28/2025HC WainwrightBoost TargetBuy ➝ Buy$38.00 ➝ $48.00
5/8/2025HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
4/16/2025HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
4/14/2025Piper SandlerInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.00
3/20/2025CitigroupBoost TargetBuy ➝ Buy$44.00 ➝ $47.00
3/18/2025TD CowenInitiated CoverageBuy$60.00
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
9/27/2024Raymond James FinancialInitiated CoverageOutperform$37.00
8/30/2024William BlairUpgradeStrong-Buy
8/15/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$36.00 ➝ $36.00
8/12/2024HC WainwrightInitiated CoverageBuy ➝ Buy$38.00 ➝ $38.00
4/15/2024Leerink PartnersReiterated RatingOutperform
4/15/2024Leerink PartnersInitiated CoverageOutperform$32.00
4/15/2024William BlairInitiated CoverageOutperform
4/10/2024CitigroupInitiated CoverageBuy$34.00
3/27/2024Piper SandlerInitiated CoverageOverweight$28.00
(Data available from 4/22/2021 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2025
  • 2 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2025
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/22/2025
  • 2 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2026
  • 6 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/21/2026

Current Sentiment

  • 6 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

LENZ Therapeutics logo
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Read More

Today's Range

Now: $9.87
Low: $9.81
High: $10.39

50 Day Range

MA: $11.14
Low: $8.29
High: $13.68

52 Week Range

Now: $9.87
Low: $8.25
High: $50.40

Volume

486,719 shs

Average Volume

1,060,832 shs

Market Capitalization

$309.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

Frequently Asked Questions

What sell-side analysts currently cover shares of LENZ Therapeutics?

The following Wall Street analysts have issued stock ratings on LENZ Therapeutics in the last year: Bank of America Corporation, Citigroup Inc., HC Wainwright, Piper Sandler, Raymond James Financial, Inc., Wall Street Zen, Weiss Ratings, William Blair, and Zacks Research.
View the latest analyst ratings for LENZ.

What is the current price target for LENZ Therapeutics?

0 Wall Street analysts have set twelve-month price targets for LENZ Therapeutics in the last year. Their average twelve-month price target is $44.00, suggesting a possible upside of 345.8%. Piper Sandler has the highest price target set, predicting LENZ will reach $67.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $26.00 for LENZ Therapeutics in the next year.
View the latest price targets for LENZ.

What is the current consensus analyst rating for LENZ Therapeutics?

LENZ Therapeutics currently has 1 sell rating, 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LENZ.

What other companies compete with LENZ Therapeutics?

Other companies that are similar to LENZ Therapeutics include Inhibrx Biosciences, Urogen Pharma, Pharming Group, AbCellera Biologics and Compass Pathways. Learn More about companies similar to LENZ Therapeutics.

How do I contact LENZ Therapeutics' investor relations team?

LENZ Therapeutics' physical mailing address is 611 Gateway Blvd Suite 120, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-484-0886 and its investor relations email address is [email protected]. The official website for LENZ Therapeutics is www.graphitebio.com. Learn More about contacing LENZ Therapeutics investor relations.